Current, Former FDA Circ Panel Chairs Stress Need For Data On PFO Devices
This article was originally published in The Gray Sheet
Executive Summary
The medical community should curtail off-label use of patent foraman ovale closure devices and support ongoing randomized trials, according to a July 20 Journal of the American Medical Association column
You may also be interested in...
Cardiologists Should Treat Stroke As A ‘Brain Attack’ With Cardiac Source
Physicians should treat stroke as a cardiac - as opposed to a neurological - event, and address structural heart defects to prevent strokes, Stephen Ramee, MD, Ochsner Clinic Foundation argued Oct. 19 at the Transcatheter Cardiovascular Therapeutics annual meeting in Washington, D.C
Cardiologists Should Treat Stroke As A ‘Brain Attack’ With Cardiac Source
Physicians should treat stroke as a cardiac - as opposed to a neurological - event, and address structural heart defects to prevent strokes, Stephen Ramee, MD, Ochsner Clinic Foundation argued Oct. 19 at the Transcatheter Cardiovascular Therapeutics annual meeting in Washington, D.C
St. Jude Expects Easy Enrollment In New PFO Study For Migraines
St. Jude Medical expects the trial of its Premere patent foramen ovale (PFO) closure device in migraine patients to enroll patients faster than trials of PFO closure to prevent stroke